A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

Frank Jessen¹, Rebecca E Amariglio², Martin van Boxtel³, Monique Breteler⁴, Mathieu Ceccaldi⁵, Gaël Chételat⁶, Bruno Dubois⁷, Carole Dufouil⁸, Kathryn A Ellis⁹, Wiesje M van der Flier¹⁰, Lidia Glodzik¹¹, Argonde C van Harten¹⁰, Mony J de Leon¹¹, Pauline McHugh¹¹, Michelle M Mielke¹², Jose Luis Molinuevo¹³, Lisa Mosconi¹¹, Ricardo S Osorio¹¹, Audrey Perrotin⁶, Ronald C Petersen¹⁴, Laura A Rabin¹⁵, Lorena Rami¹³, Barry Reisberg¹⁶, Dorene M Rentz², Perminder S Sachdev¹⁷, Vincent de la Sayette⁶, Andrew J Saykin¹⁸, Philip Scheltens¹⁰, Melanie B Shulman¹¹, Melissa J Slavin¹⁹, Reisa A Sperling², Robert Stewart²⁰, Olga Uspenskaya²¹, Bruno Vellas²², Pieter Jelle Visser²³, Michael Wagner²⁴; Subjective Cognitive Decline Initiative (SCD-I) Working Group

Affiliations

¹ Department of Psychiatry, University of Bonn, Bonn, Germany; Clinical Treatment and Research Center for Neurodegenerative Disease (KBFZ), University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. Electronic address: frank.jessen@ukb.uni-bonn.de.
² Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Boston, MA, USA.
³ Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands.
⁴ German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
⁵ Institut des Neurosciences des Systèmes, Université de Marseille, Marseille, France.
⁶ INSERM, U1077, Caen, France; Université de Caen Basse-Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France.
⁷ Université Pierre et Marie Curie, Paris, France.
⁸ INSERM U708, Neuroepidemiology, CIC-EC7 and Bordeaux University, Bordeaux, France.
⁹ Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Australia.
¹⁰ Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
¹¹ Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA.
¹² Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
¹³ Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Hospital Clinic, Barcelona, Spain.
¹⁴ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
¹⁵ Brooklyn College of The City University of New York, New York, NY, USA; The Graduate Center of The City University of New York, New York, NY, USA.
¹⁶ Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA; Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, NY, USA.
¹⁷ Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia.
¹⁸ Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.
¹⁹ Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney, Australia.
²⁰ Institute of Psychiatry, King's College London, London, UK.
²¹ Alzheimer's Institute, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
²² Department of Internal Medicine and Geriatrics, Toulouse University Hospital, UMR INSERM 1027, University Paul Sabatier, Toulouse, France.
²³ Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands; Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
²⁴ Department of Psychiatry, University of Bonn, Bonn, Germany; Clinical Treatment and Research Center for Neurodegenerative Disease (KBFZ), University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

PMID: 24798886
PMCID: PMC4317324
DOI: 10.1016/j.jalz.2014.01.001

Review

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

Frank Jessen et al. Alzheimers Dement. 2014 Nov.

. 2014 Nov;10(6):844-52.

doi: 10.1016/j.jalz.2014.01.001. Epub 2014 May 3.

Authors

Affiliations

¹ Department of Psychiatry, University of Bonn, Bonn, Germany; Clinical Treatment and Research Center for Neurodegenerative Disease (KBFZ), University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. Electronic address: frank.jessen@ukb.uni-bonn.de.
² Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Boston, MA, USA.
³ Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands.
⁴ German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
⁵ Institut des Neurosciences des Systèmes, Université de Marseille, Marseille, France.
⁶ INSERM, U1077, Caen, France; Université de Caen Basse-Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France.
⁷ Université Pierre et Marie Curie, Paris, France.
⁸ INSERM U708, Neuroepidemiology, CIC-EC7 and Bordeaux University, Bordeaux, France.
⁹ Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Australia.
¹⁰ Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
¹¹ Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA.
¹² Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
¹³ Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Hospital Clinic, Barcelona, Spain.
¹⁴ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
¹⁵ Brooklyn College of The City University of New York, New York, NY, USA; The Graduate Center of The City University of New York, New York, NY, USA.
¹⁶ Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA; Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, NY, USA.
¹⁷ Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia.
¹⁸ Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.
¹⁹ Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney, Australia.
²⁰ Institute of Psychiatry, King's College London, London, UK.
²¹ Alzheimer's Institute, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
²² Department of Internal Medicine and Geriatrics, Toulouse University Hospital, UMR INSERM 1027, University Paul Sabatier, Toulouse, France.
²³ Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands; Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
²⁴ Department of Psychiatry, University of Bonn, Bonn, Germany; Clinical Treatment and Research Center for Neurodegenerative Disease (KBFZ), University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

PMID: 24798886
PMCID: PMC4317324
DOI: 10.1016/j.jalz.2014.01.001

Abstract

There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD-I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre-mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus.

Keywords: Alzheimer's disease; Mild cognitive impairment; Preclinical Alzheimer's disease; Prodromal Alzheimer 's disease; Research criteria; Subjective cognitive decline.

PubMed Disclaimer

Figures

**Fig. 1**
Depicted is the course of cognitive decline in relation to progressive disease pathology in Alzheimer’s disease (AD). After a phase of stable cognitive performance in the presence of increasing pathology, cognitive decline occurs. After crossing the threshold of below normal age-, sex-, and education-adjusted performance, the stage of mild cognitive impairment (MCI) or prodromal AD is reached. Subsequently, cognitive decline progresses onward to the stage of dementia. It is proposed that SCD occurs at the late stage of preclinical AD, which is characterized by increasing compensatory cognitive efforts and subtle cognitive decline. Thus, SCD may indicate the late-stage preclinical AD before the threshold of MCI/prodromal AD is reached. There is evidence that the subjective experience of decline levels off as disease progresses into dementia. That stage, however, is not part of the conceptualization of SCD in preclinical AD and is not addressed in the present publication.

See this image and copyright information in PMC

Comment in

Issues about the use of subjective cognitive decline in Alzheimer's disease research.
Canevelli M, Blasimme A, Vanacore N, Bruno G, Cesari M. Canevelli M, et al. Alzheimers Dement. 2014 Nov;10(6):881-2. doi: 10.1016/j.jalz.2014.07.154. Epub 2014 Sep 22. Alzheimers Dement. 2014. PMID: 25248820 No abstract available.

References

1. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, et al. Prevention trials in Alzheimer’s disease: an EU-US task force report. Prog Neurobiol. 2011;95:594–600. - PubMed
1. Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16. - PMC - PubMed
1. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. - PubMed
1. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9:560–74. - PubMed
1. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–46. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

UL1 TR001108/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect - Access expert opinions and insights on biomedical research.
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

Affiliations

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

Authors

Affiliations

Abstract

Figures

Comment in

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical